TABLE 2.
Study | Year | Randomization | Allocation concealment | Blinding of participants and staff a | Blinding of outcome assessors | Incomplete outcome data | Selective outcome reporting | Other sources of bias |
---|---|---|---|---|---|---|---|---|
AdamsA | 2018 | Low | Low | Low | Low | Low | Low | Low |
AdamsB | 2018 | Low | Low | Low | Low | Low | Low | Low |
Emens | 2018 | Low | Low | Low | Low | Low | Low | Low |
Rugo | 2018 | Low | Low | Low | Low | Low | Low | Low |
Dirix | 2017 | Low | Low | Low | Low | Low | Low | Low |
Nanda | 2016 | Low | Low | Low | Low | Low | Low | Low |
Kappa | NA | 1.00 | 1.00 | 1.00 | 0.629 | 1.00 | 1.00 | 1.00 |
NA = not applicable.
Blinding of participants and personnel was evaluated as low risk item because some studies were dose-escalation and single-arm trials. The overall risk of bias was evaluated as low risk.